International medical device and pharmaceuticals consultant Dr Raffaella Giardino has joined the team at Microbio to drive commercialisation of the product suite in Europe.
Read more in the announcement: 211214_Microbio_welcomes_Raffaella_Giardino
Microbio is pleased to announce it has appointed a distributor in India for its range of COVID-19 tests.
The appointment of Indian firm, BioGTech, follows the approval of Microbio’s COVID-19 tests by the Indian Council of Medical Research (ICMR), and validation testing by Rajiv Gandhi Centre for Biotechnology (RGCB). The first deliveries to India are expected to be made in coming weeks.
Find out more in the media release: 211209_Microbio_prepares_for_first_deliveries_in_India
Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.
More information can be found in the media release.
211019_Microbio_moves_toward_sovereign_manufacturing_of_diagnostic_tests
Microbio is pleased to announce its two COVID-19 tests have been approved for sale in Europe under the IVD Directive 98/79/EC.
More information can be found in the media release.
Microbio Pty Ltd, an Australian-owned biotech company has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise Microbio’s InfectID-Blood Stream Infection (BSI) diagnostic assay. Read more in the full media release.
Microbio has developed a new type of COVID-19 test that has the potential to determine not only if someone has the virus but also if they are infectious.
Microbio today announced its ground-breaking InfectID-COVID-19-R test which has been independently validated to identify the presence of replication-competent SARS-CoV-2 virus in samples in 45 minutes (post RNA extraction).
The full press kit and accompanying photographs can be found in this dropbox.